The IMATUS researcher is leading the development of this Class III medical device that combines materials science and pharmacology to revolutionize maxillofacial surgery. At the International Dental Equipment, Products and Services Exhibition (Expodental 2026), Dr. Mario Pérez-Sayáns presented the results of the Galibone+ clinical trial. This new biomaterial promises to be a game-changer in bone regeneration procedures and implant surgery.
A Next-Generation Biomaterial
Galibone+ is not a conventional material. It is a Class III medical device with added medicinal content, developed by a consortium comprised of the University of Santiago de Compostela (USC), the University of Murcia (UMU), and the company Galimplant.
Its technical composition includes: Beta-tricalcium phosphate, hydroxyapatite, and a pharmacological active ingredient specifically designed to enhance tissue repair.
“The project was approached from a comprehensive perspective, combining physicochemical characterization studies, in vitro biological assays, and in vivo subclinical evaluation, culminating in a human clinical trial approved by the Spanish Agency for Medicines and Health Products (AEMPS),” Dr. Pérez-Sayáns stated during his presentation.
From the Laboratory to the Clinic: Translational Research
The development of Galibone+, funded by the Spanish Ministry of Science and Innovation, has followed a rigorous scientific path to guarantee its safety and efficacy:
Analytical Phase: Physicochemical tests to ensure stability and optimal interaction with the biological environment.
Biological Phase: Studies in cell lines (osteoblasts and vascular endothelial cells) that confirmed its ability to promote cell adhesion and proliferation.
Preclinical Phase: Trials in animal models that validated the integration of the biomaterial into bone tissue.
Clinical Trial: Evaluated in humans using a model of impacted third molars, providing solid evidence of its healing and regenerative capacity.
Impact on the Dental Sector
According to the IMATUS researcher, the results presented support the claim that Galibone+ has a solid scientific basis for its use in alveolar ridge preservation, bone defects, and complex surgeries.
Pérez-Sayáns, who co-leads the project with Dr. Fabio Camacho Alonso, emphasized that this advancement is a perfect example of translational research: “We have successfully translated the results obtained in the laboratory into a real-world clinical application that will improve patients’ quality of life.”